Claire Manuszak1, Khanh T Do2, Emily Thrash1, Anita Giobbie-Hurder3, Jiani Hu3, Sarah Kelland4, Allison Powers4, Adrienne de Jonge4, Geoffrey I Shapiro4, Mariano Severgnini1. 1. Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, USA. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue-DA2010, Boston, MA, 02215, USA. khanhdomd@gmail.com. 3. Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, USA. 4. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue-DA2010, Boston, MA, 02215, USA.
Abstract
BACKGROUND: Checkpoint kinase 1 (CHK1) has dual roles in both the DNA damage response and in the innate immune response to genotoxic stress. The combination of CHK1 inhibition and immune checkpoint blockade has the potential to enhance anti-tumoral T-cell activation. METHODS: This was an open-label phase 1 study evaluating the CHK1 inhibitor prexasertib and the anti-PD-L1 antibody LY3300054. After a lead-in of LY3300054 (Arm A), prexasertib (Arm B) or the combination (Arm C), both agents were administered intravenously at their respective recommended phase 2 doses (RP2Ds) on days 1 and 15 of a 28-day cycle. Flow cytometry of peripheral blood was performed before and during treatment to analyze effects on immune cell populations, with a focus on T cell subsets and activation. Plasma cytokines and chemokines were analyzed using the Luminex platform. RESULTS: Among seventeen patients enrolled, the combination was tolerable at the monotherapy RP2Ds, 105 mg/m2 prexasertib and 700 mg LY3300054. Dose-limiting toxicities included one episode each of febrile neutropenia (Arm C) and grade 4 neutropenia lasting > 5 days (Arm B). One patient had immune-related AST/ALT elevation after 12 cycles. Three patients with CCNE1-amplified, high-grade serous ovarian cancer (HGSOC) achieved partial response (PR), 2 lasting > 12 months; a fourth such patient maintained stable disease > 12 months. Analysis of peripheral blood demonstrated evidence of CD8 + T-cell activation in response to treatment. CONCLUSIONS: Prexasertib in combination with PD-L1 blockade was tolerable and demonstrated preliminary activity in CCNE1-amplified HGSOC with evidence of cytotoxic T-cell activation in patient blood samples. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03495323. Registered April 12, 2018.
BACKGROUND:Checkpoint kinase 1 (CHK1) has dual roles in both the DNA damage response and in the innate immune response to genotoxic stress. The combination of CHK1 inhibition and immune checkpoint blockade has the potential to enhance anti-tumoral T-cell activation. METHODS: This was an open-label phase 1 study evaluating the CHK1 inhibitor prexasertib and the anti-PD-L1 antibody LY3300054. After a lead-in of LY3300054 (Arm A), prexasertib (Arm B) or the combination (Arm C), both agents were administered intravenously at their respective recommended phase 2 doses (RP2Ds) on days 1 and 15 of a 28-day cycle. Flow cytometry of peripheral blood was performed before and during treatment to analyze effects on immune cell populations, with a focus on T cell subsets and activation. Plasma cytokines and chemokines were analyzed using the Luminex platform. RESULTS: Among seventeen patients enrolled, the combination was tolerable at the monotherapy RP2Ds, 105 mg/m2 prexasertib and 700 mg LY3300054. Dose-limiting toxicities included one episode each of febrile neutropenia (Arm C) and grade 4 neutropenia lasting > 5 days (Arm B). One patient had immune-related AST/ALT elevation after 12 cycles. Three patients with CCNE1-amplified, high-grade serous ovarian cancer (HGSOC) achieved partial response (PR), 2 lasting > 12 months; a fourth such patient maintained stable disease > 12 months. Analysis of peripheral blood demonstrated evidence of CD8 + T-cell activation in response to treatment. CONCLUSIONS:Prexasertib in combination with PD-L1 blockade was tolerable and demonstrated preliminary activity in CCNE1-amplified HGSOC with evidence of cytotoxic T-cell activation in patient blood samples. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03495323. Registered April 12, 2018.
Authors: Alexandre André B A da Costa; Dipanjan Chowdhury; Geoffrey I Shapiro; Alan D D'Andrea; Panagiotis A Konstantinopoulos Journal: Nat Rev Drug Discov Date: 2022-10-06 Impact factor: 112.288
Authors: Benjamin Margolis; Fanny Dao; Michael Licciardi; Selim Misirlioglu; Narciso Olvera; Sitharam Ramaswami; Douglas A Levine Journal: Gynecol Oncol Rep Date: 2021-08-21
Authors: Vincent T Ho; Haesook T Kim; Jennifer Brock; Ilene Galinsky; Heather Daley; Carol Reynolds; Augustine Weber; Olga Pozdnyakova; Mariano Severgnini; Sarah Nikiforow; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Mahasweta Gooptu; Rizwan Romee; Roman Shapiro; Yi-Bin Chen; Jacalyn Rosenblatt; David Avigan; F Stephen Hodi; Glenn Dranoff; Catherine J Wu; Jerome Ritz; Robert J Soiffer Journal: Blood Adv Date: 2022-04-12